Neuronetics Stock Performance
| STIM Stock | USD 1.27 0.02 1.55% |
Neuronetics has a performance score of 1 on a scale of 0 to 100. The company secures a Beta (Market Risk) of 2.81, which conveys a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Neuronetics will likely underperform. Neuronetics right now secures a risk of 7.33%. Please verify Neuronetics downside variance, as well as the relationship between the accumulation distribution and price action indicator , to decide if Neuronetics will be following its current price movements.
Risk-Adjusted Performance
Weak
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Neuronetics are ranked lower than 1 (%) of all global equities and portfolios over the last 90 days. In spite of very uncertain forward indicators, Neuronetics may actually be approaching a critical reversion point that can send shares even higher in April 2026. ...more
| Begin Period Cash Flow | 59.7 M | |
| Total Cashflows From Investing Activities | -2.4 M |
Neuronetics | Build AI portfolio with Neuronetics Stock |
Neuronetics Relative Risk vs. Return Landscape
If you would invest 134.00 in Neuronetics on December 3, 2025 and sell it today you would lose (7.00) from holding Neuronetics or give up 5.22% of portfolio value over 90 days. Neuronetics is currently generating 0.1676% in daily expected returns and assumes 7.3269% risk (volatility on return distribution) over the 90 days horizon. In different words, 65% of stocks are less volatile than Neuronetics, and 97% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Neuronetics Target Price Odds to finish over Current Price
The tendency of Neuronetics Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 1.27 | 90 days | 1.27 | about 87.15 |
Based on a normal probability distribution, the odds of Neuronetics to move above the current price in 90 days from now is about 87.15 (This Neuronetics probability density function shows the probability of Neuronetics Stock to fall within a particular range of prices over 90 days) .
Neuronetics Price Density |
| Price |
Predictive Modules for Neuronetics
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Neuronetics. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Neuronetics Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Neuronetics is not an exception. The market had few large corrections towards the Neuronetics' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Neuronetics, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Neuronetics within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | 0.05 | |
β | Beta against Dow Jones | 2.81 | |
σ | Overall volatility | 0.30 | |
Ir | Information ratio | 0.02 |
Neuronetics Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Neuronetics for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Neuronetics can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Neuronetics had very high historical volatility over the last 90 days | |
| Neuronetics may become a speculative penny stock | |
| Neuronetics has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 74.89 M. Net Loss for the year was (43.73 M) with profit before overhead, payroll, taxes, and interest of 66.1 M. | |
| Neuronetics currently holds about 73.7 M in cash with (31 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.71, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 62.0% of the company shares are owned by institutional investors |
Neuronetics Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Neuronetics Stock often depends not only on the future outlook of the current and potential Neuronetics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Neuronetics' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 31.7 M | |
| Cash And Short Term Investments | 19.7 M |
Neuronetics Fundamentals Growth
Neuronetics Stock prices reflect investors' perceptions of the future prospects and financial health of Neuronetics, and Neuronetics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Neuronetics Stock performance.
| Return On Equity | -2.19 | ||||
| Return On Asset | -0.21 | ||||
| Profit Margin | (0.34) % | ||||
| Operating Margin | (0.20) % | ||||
| Current Valuation | 154.03 M | ||||
| Shares Outstanding | 68.49 M | ||||
| Price To Book | 3.34 X | ||||
| Price To Sales | 0.68 X | ||||
| Revenue | 74.89 M | ||||
| EBITDA | (34.37 M) | ||||
| Cash And Equivalents | 73.7 M | ||||
| Cash Per Share | 2.71 X | ||||
| Total Debt | 82.63 M | ||||
| Debt To Equity | 0.63 % | ||||
| Book Value Per Share | 0.40 X | ||||
| Cash Flow From Operations | (31 M) | ||||
| Earnings Per Share | (0.83) X | ||||
| Total Asset | 140.9 M | ||||
| Retained Earnings | (419.79 M) | ||||
About Neuronetics Performance
By examining Neuronetics' fundamental ratios, stakeholders can obtain critical insights into Neuronetics' financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Neuronetics is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
Neuronetics, Inc., a commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United States and internationally. Neuronetics, Inc. was incorporated in 2001 and is headquartered in Malvern, Pennsylvania. Neuronetics operates under Diagnostics Research classification in the United States and is traded on NASDAQ Exchange. It employs 198 people.Things to note about Neuronetics performance evaluation
Checking the ongoing alerts about Neuronetics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Neuronetics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Neuronetics had very high historical volatility over the last 90 days | |
| Neuronetics may become a speculative penny stock | |
| Neuronetics has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 74.89 M. Net Loss for the year was (43.73 M) with profit before overhead, payroll, taxes, and interest of 66.1 M. | |
| Neuronetics currently holds about 73.7 M in cash with (31 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.71, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 62.0% of the company shares are owned by institutional investors |
- Analyzing Neuronetics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Neuronetics' stock is overvalued or undervalued compared to its peers.
- Examining Neuronetics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Neuronetics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Neuronetics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Neuronetics' stock. These opinions can provide insight into Neuronetics' potential for growth and whether the stock is currently undervalued or overvalued.
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Neuronetics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. To learn how to invest in Neuronetics Stock, please use our How to Invest in Neuronetics guide.You can also try the Equity Valuation module to check real value of public entities based on technical and fundamental data.
Will Health Care Equipment & Supplies sector continue expanding? Could Neuronetics diversify its offerings? Factors like these will boost the valuation of Neuronetics. If investors know Neuronetics will grow in the future, the company's valuation will be higher. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Neuronetics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Neuronetics's market price often diverges from its book value, the accounting figure shown on Neuronetics's balance sheet. Smart investors calculate Neuronetics' intrinsic value - its true economic worth - which may differ significantly from both market price and book value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Since Neuronetics' trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
Please note, there is a significant difference between Neuronetics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Neuronetics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Neuronetics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.